Anonymous1 day ago
Scientists and pharmaceutical companies are racing to develop broad-spectrum vaccines capable of targeting multiple pathogens with a single injection, using platforms like mRNA and mosaic nanoparticles. While billions of dollars in public and private funding are flowing into these programs — with clinical trials for universal influenza and coronavirus vaccines scheduled through 2029 — the approach faces steep scientific, regulatory, and equity hurdles, and historical precedent suggests caution about overpromising.